Garcinol induces lysosome-dependent p300/FOXP3 degradation and limits Treg cell functions to enhance targeted therapy against cancers

Experimental and Molecular Pathology

Volumn 95, Issue 1, 2013, Pages 38-45

  Du, Taofeng ^a,b   Nagai, Yasuhiro ^a   Xiao, Yan ^a   Greene, Mark I ^a   Zhang, Hongtao ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b JILIN UNIVERSITY   (China)

Author keywords

Acetyltransferase; FOXP3; Garcinol; Lysosome degradation; P300; Regulatory T cells; Treg

Indexed keywords

BENZYLOXYCARBONYLLEUCYLLEUCYLLEUCINAL; CHLOROQUINE; E1A ASSOCIATED P300 PROTEIN; GARCINOL; N [N (3 CARBOXYOXIRANE 2 CARBONYL)LEUCYL]AGMATINE; PEPSTATIN; TRANSCRIPTION FACTOR FOXP3; UNCLASSIFIED DRUG; ACYLTRANSFERASE; ANTINEOPLASTIC AGENT; ENZYME INHIBITOR; EP300 PROTEIN, HUMAN; FORKHEAD TRANSCRIPTION FACTOR; FOXP3 PROTEIN, HUMAN; HISTONE ACETYLTRANSFERASE; KAT5 PROTEIN, HUMAN; TERPENE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL ACTIVITY; CELL FUNCTION; CONTROLLED STUDY; ENZYME DEGRADATION; ENZYME REGULATION; FEMALE; HISTONE ACETYLATION; HUMAN; HUMAN CELL; IN VIVO STUDY; MALIGNANT NEOPLASTIC DISEASE; MOLECULARLY TARGETED THERAPY; MOUSE; NONHUMAN; PROTEIN FUNCTION; PROTEIN STABILITY; REGULATORY T LYMPHOCYTE; SUPPRESSOR CELL; ACETYLATION; ANIMAL; BAGG ALBINO MOUSE; CELL LINE; DRUG ANTAGONISM; DRUG EFFECT; DRUG SCREENING; FOXP3; GENETICS; IMMUNOLOGY; LYSOSOME; LYSOSOME DEGRADATION; METABOLISM; METHODOLOGY; MUTATION; P300; T(REG);

MOUSE MAMMARY TUMOR VIRUS;

ACETYLTRANSFERASE; FOXP3; GARCINOL; LYSOSOME DEGRADATION; P300; REGULATORY T CELLS; T(REG);

ACETYLATION; ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CELL LINE; CHLOROQUINE; E1A-ASSOCIATED P300 PROTEIN; ENZYME INHIBITORS; FEMALE; FORKHEAD TRANSCRIPTION FACTORS; HISTONE ACETYLTRANSFERASES; HUMANS; LYSOSOMES; MICE; MICE, INBRED BALB C; MOLECULAR TARGETED THERAPY; MUTATION; T-LYMPHOCYTES, REGULATORY; TERPENES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84878365978     PISSN: 00144800     EISSN: 10960945     Source Type: Journal    
DOI: 10.1016/j.yexmp.2013.04.003     Document Type: Article

References (39)

1. Ahmad A., et al. Garcinol regulates EMT and Wnt signaling pathways in vitro and in vivo leading to anticancer activity against breast cancer cells. Molecular Cancer Therapeutics 2012, 11:2193-2201.
2. Allan S.E., et al. The role of 2 FOXP3 isoforms in the generation of human CD4+ Tregs. The Journal of Clinical Investigation 2005, 115:3276-3284.
3. Arif M., et al. Autoacetylation induced specific structural changes in histone acetyltransferase domain of p300: probed by surface enhanced Raman spectroscopy. The Journal of Physical Chemistry. B 2007, 111:11877-11879.
4. Balasubramanyam K., et al. Polyisoprenylated benzophenone, garcinol, a natural histone acetyltransferase inhibitor, represses chromatin transcription and alters global gene expression. The Journal of Biological Chemistry 2004, 279:33716-33726.
5. Beier U.H., et al. Histone/protein deacetylases control Foxp3 expression and the heat shock response of T-regulatory cells. Current Opinion in Immunology 2011, 23:670-678.
6. Boya P., et al. Mitochondrial membrane permeabilization is a critical step of lysosome-initiated apoptosis induced by hydroxychloroquine. Oncogene 2003, 22:3927-3936.
7. Cai Z., et al. scFv-based 'Grababody' as a general strategy to improve recruitment of immune effector cells to antibody-targeted tumors. Cancer Research 2013, 73:2619-2627.
8. Chen J., Li Q. Life and death of transcriptional co-activator p300. Epigenetics 2011, 6:957-961.
9. de Zoeten E.F., et al. Inhibition of HDAC9 increases T regulatory cell function and prevents colitis in mice. Gastroenterology 2010, 138:583-594.
10. de Zoeten E.F., et al. Histone deacetylase 6 and heat shock protein 90 control the functions of Foxp3(+) T-regulatory cells. Molecular and Cellular Biology 2011, 31:2066-2078.
11. Drebin J.A., et al. Monoclonal antibodies identify a cell-surface antigen associated with an activated cellular oncogene. Nature 1984, 312:545-548.
12. Drebin J.A., et al. Inhibition of tumor growth by a monoclonal antibody reactive with an oncogene-encoded tumor antigen. Proceedings of the National Academy of Sciences of the United States of America 1986, 83:9129-9133.
13. Hori S., et al. Control of regulatory T cell development by the transcription factor Foxp3. Science 2003, 299:1057-1061.
14. Jain S., et al. Auto-acetylation stabilizes p300 in cardiac myocytes during acute oxidative stress, promoting STAT3 accumulation and cell survival. Breast Cancer Research and Treatment 2012, 135:103-114.
15. Katsumata M., et al. Prevention of breast tumour development in vivo by downregulation of the p185neu receptor. Nature Medicine 1995, 1:644-648.
16. Kerkar S.P., Restifo N.P. Cellular constituents of immune escape within the tumor microenvironment. Cancer Research 2012, 72:3125-3130.
17. Kwon H.S., et al. Three novel acetylation sites in the Foxp3 transcription factor regulate the suppressive activity of regulatory T cells. Journal of Immunology 2012, 188:2712-2721.
18. Li B., Greene M.I. FOXP3 actively represses transcription by recruiting the HAT/HDAC complex. Cell Cycle 2007, 6:1432-1436.
19. Li B., et al. FOXP3 interactions with histone acetyltransferase and class II histone deacetylases are required for repression. Proceedings of the National Academy of Sciences of the United States of America 2007, 104:4571-4576.
20. Mantelingu K., et al. Specific inhibition of p300-HAT alters global gene expression and represses HIV replication. Chemistry & Biology 2007, 14:645-657.
21. Masuda K., et al. AHNP-streptavidin: a tetrameric bacterially produced antibody surrogate fusion protein against p185her2/neu. Oncogene 2006, 25:7740-7746.
22. Merlo A., et al. FOXP3 expression and overall survival in breast cancer. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 2009, 27:1746-1752.
23. Padhye S., et al. Emerging role of Garcinol, the antioxidant chalcone from Garcinia indica Choisy and its synthetic analogs. Journal of Hematology & Oncology 2009, 2:38.
24. Park S., et al. The therapeutic effect of anti-HER2/neu antibody depends on both innate and adaptive immunity. Cancer Cell 2010, 18:160-170.
25. Poizat C., et al. Phosphorylation-dependent degradation of p300 by doxorubicin-activated p38 mitogen-activated protein kinase in cardiac cells. Molecular and Cellular Biology 2005, 25:2673-2687.
26. Saadat N., Gupta S.V. Potential role of Garcinol as an anticancer agent. Journal of Oncology 2012, 2012:647206.
27. Samanta A., et al. TGF-beta and IL-6 signals modulate chromatin binding and promoter occupancy by acetylated FOXP3. Proceedings of the National Academy of Sciences of the United States of America 2008, 105:14023-14027.
28. Saouaf S.J., et al. Deacetylase inhibition increases regulatory T cell function and decreases incidence and severity of collagen-induced arthritis. Experimental and Molecular Pathology 2009, 87:99-104.
29. Song X., et al. Structural and biological features of FOXP3 dimerization relevant to regulatory T cell function. Cell Reports 2012, 1:665-675.
30. Stagg J., et al. Antibodies targeted to TRAIL receptor-2 and ErbB-2 synergize in vivo and induce an antitumor immune response. Proceedings of the National Academy of Sciences of the United States of America 2008, 105:16254-16259.
31. Stagg J., et al. Anti-ErbB-2 mAb therapy requires type I and II interferons and synergizes with anti-PD-1 or anti-CD137 mAb therapy. Proceedings of the National Academy of Sciences of the United States of America 2011, 108:7142-7147.
32. van Loosdregt J., et al. Regulation of Treg functionality by acetylation-mediated Foxp3 protein stabilization. Blood 2010, 115:965-974.
33. Wan Y.Y., Flavell R.A. Regulatory T-cell functions are subverted and converted owing to attenuated Foxp3 expression. Nature 2007, 445:766-770.
34. Williams L.M., Rudensky A.Y. Maintenance of the Foxp3-dependent developmental program in mature regulatory T cells requires continued expression of Foxp3. Nature Immunology 2007, 8:277-284.
35. Xiao Y., et al. Histone acetyltransferase mediated regulation of FOXP3 acetylation and Treg function. Current Opinion in Immunology 2010, 22:583-591.
36. Zhang H., et al. Shared antigenic epitopes and pathobiological functions of anti-p185(her2/neu) monoclonal antibodies. Experimental and Molecular Pathology 1999, 67:15-25.
37. Zhang H., et al. Immune regulation by histone deacetylases: a focus on the alteration of FOXP3 activity. Immunology & Cell Biology 2012, 90:95-100.
38. Zhang H., et al. Monoclonal antibodies for cancer therapy and prevention: paradigm studies in targeting the neu/ERBB2/HER2 oncoprotein. Cancer Immunotherapy: Immune Suppression and Tumor Growth 2012, 2nd edition. G.C. Prendergast, E.M. Jeffee (Eds.).
39. Ziegler S.F. FOXP3: of mice and men. Annual Review of Immunology 2006, 24:209-226.